... Abstract Mycophenolate mophetil (MMP) is a potent immunomodulatory drug that inhibits the function of T and B lymphocytes. It is used successfully in the treatment of recurrent noninfectious uveitis in adults and children. MMF can be used alone or in combination with other immunomodulatory...

... concepts such as induction therapy and maintenance therapy. In LN induction therapy until recently, cyclophosphamide in combination with prednisone (PSL) has been the standard method of treatment for proliferative forms of LN. In the latest review, the combination of mycophenolate mofetil (MMF) is also...

... nature of IgAN, therapy with mycophenolate mofetil (MMF), a potent immunosuppressive agent, could be effective in patients at risk for progressive disease. In this paper, we discuss the case of an IgAN patient treated with MMF at our center, followed by a review of the literature and our previous...

... the long-term prognosis of IgAN remains unclear, since it has not yet been tested in acontrolled randomized trial. The role of mycophenolate mofetil (MMF) in IgAN has beenexamined in four major trials. Two prospective randomized studies report no benefit fromMMF. The remaining two studies showed a greater...

... ocular disease. Further clinical studies are required to expand on their use in uveitis patients. Antimetabolites Mycophenolate Mofetil Key Features, Introduction and History Mycophenolate mofetil (MMF) is a prodrug of the mycophenolic acid derived from the fungus Penicillium stoloniferum...

... of IgAN patients with proteinuria ≥1 g/24 h and plasma creatinine ≤2.0 mg/dl. Current data therefore suggest that the addition of azathioprine was ineffective and may even be potentially toxic. Mycophenolate Mofetil The first clinical report of MMF in IgAN was in the prevention of progression...

... the use of steroids and cyclophosphamide in patients with rapidly progressive crescentic IgA nephropathy, analogous to the treatment of ANCA vasculitis (2D) [ 5 ]. RCTs are necessary for investigating the exact benefits of corticosteroids, cyclophosphamide, MMF and azathioprine in crescentic IgA...

... of immunosuppressive drugs, including tacrolimus (FK), mycophenolate mofetil (MMF) and methylprednisolone (MP). Between January 2001 and December 2004, all patients underwent pretransplant double filtration plasmapheresis (DFPP) and splenectomy at the time of transplant (n = 46) (ABO-I-SPX group). Between January 2005...

... children screened for normal TPMT levels before therapy, no myelosuppression was observed under treatment with 2.5-3.5 mg/kg azathioprine for severe AD [ 20 ]. Out of these patients, 28 had an excellent and 13 a good response to azathioprine [ 20 ]. Mycophenolate Mofetil Mycophenolate mofetil (MMF...

... with a worse outcome [ 31 ]. Antimetabolites Mycophenolate mofetil (MMF) and mycophenolic acid are inhibitors of the metabolism of pyrimidines and have replaced azathioprine in most transplant centers as a standard immunosuppressive drug, in combination with CNI and steroids. Despite being a more potent...

... disorders. Steroid-sparing agents including calcineurin inhibitors (CNIs), cyclophosphamide (CTX), and mycophenolate mofetil (MMF) are often used to treat these children. From 10 to 20% of the patients are resistant to steroids (SRNS) and half of them will advance to end-stage renal failure. For children...

... of function at 3 years in the treatment group. Glucocorticoid Combined with Mycophenolate Mofetil (MMF) The effect of MMF treatment in patients with progressive IgAN has been evaluated by researchers from China, Belgium, and the USA. One Chinese study reported that compared with high-dose oral...

... of herpes simplex keratitis require daily dosages of 800-1,000 mg per day over 6-12 months [ 35 , 36 ]. In cases with a high risk of immune rejection and herpes keratitis recurrence, mycophenolate mofetil (MMF) should be added at 2 × 1 g per day for 6-12 months [ 37 ]. Systemic steroids should...

... 6 months, continued breastfeeding for 1 year, introduction of solid, semi-solid, or soft foods, consumption of iron-rich or iron-fortified foods, minimum dietary diversity (MDD), minimum meal frequency (MMF), and minimum acceptable diet (MAD) [ 16 ]. These indicators provide the ability to evaluate...

... ]. If younger children were included, comprising those aged 6-23 months, only 33.5% of the children obtained the MDD 1 , 78.6% had an age-appropriate minimum meal frequency (MMF), and only 28.2% received a minimum acceptable diet (MAD) [ 9 , 16 ]. In 2012, a randomized controlled trial (RCT) was started...

..., 27.3% of them are resistant to steroid therapy. Steroid-dependent and steroid-resistant MCD are treated with a combination of prednisone and immunosuppressant agents such as cyclosporin A (CsA), cyclophosphamide (CTX), mycophenolate mofetil (MMF) and tacrolimus. A clinical study showed a 93% response...

... with a focus on kidney transplantation and the possible impact of these new approaches on the incidence of skin cancer. The introduction of the calcineurin inhibitors (CNIs) cyclosporine (CsA) in the 1980s and tacrolimus (FK) and the anti-metabolite mycofenolate-mofetil (MMF) in the 1990s into clinical...

... of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-1849 21. Frisch G, Lin J, Rosenstock J, et al: Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20...

...-for-height z-scores, with the exception of minimum meal frequency (MMF) in one country (Uganda), and associations with stunting or wasting were generally not statistically significant. No associations were found between consumption of iron-rich foods and child anthropometry in any of the 5 countries...